Study guide

6.6: Respiratory Therapeutics (Asthma & COPD)

Overseas Pharmacist Readiness Assessment OPRA

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1: About the OPRA Exam 1.2: Study and Preparation Strategy for OPRA

2 Chapter 2: Biomedical Sciences

2.1: Human Physiology & Homeostasis 2.2: Pathophysiology of Major Organ Systems 2.3: Medical Microbiology & Infectious Pathogens 2.4: Immunology & Immunotherapy 2.5: Body Fluids, Electrolytes, & Acid-Base Balance 2.6: Physiological Values & Clinical Lab Interpretations

3 Chapter 3: Medicinal Chemistry & Biopharmaceutics

3.1: Physicochemical Properties of Drugs 3.2: Biopharmaceutics & Formulation Science 3.3: Chemical Stability & Storage of Pharmaceuticals 3.4: Sterile Compounding & Pharmaceutical Microbiology

4 Chapter 4: Pharmacokinetics & Pharmacodynamics

4.1: Principles of Pharmacokinetics (Absorption & Distribution) 4.2: Drug Metabolism & Elimination Pathways 4.3: Quantitative Pharmacokinetics (Vd, Clearance, Half-life, Steady-state) 4.4: Clinical Pharmacokinetics (Dosing Adjustments & Non-linear Kinetics) 4.5: Pharmacodynamics & Receptor Theory

5 Chapter 5: Pharmacology & Toxicology

5.1: Mechanisms of Action: Cardiovascular & Renal Agents 5.2: Mechanisms of Action: Respiratory, CNS, & Endocrine Agents 5.3: Adverse Drug Reactions & Drug-Drug Interactions 5.4: Clinical Toxicology & Poisoning Management 5.5: Pharmacogenomics & Genetic Polymorphism

6 Chapter 6: Therapeutics & Patient Care

6.1: Pharmaceutical Calculations: Doses & Unit Conversions 6.2: Pharmaceutical Calculations: Infusions, Percentages, & Tonicity 6.3: Cardiovascular Therapeutics (Hypertension, Heart Failure, Dyslipidemia) 6.4: Anticoagulation & Antiplatelet Therapy 6.5: Endocrine & Metabolic Therapeutics (Diabetes & Thyroid) 6.6: Respiratory Therapeutics (Asthma & COPD) 6.7: Infectious Disease Therapeutics & Antimicrobial Stewardship 6.8: Central Nervous System & Mental Health Therapeutics 6.9: Gastrointestinal & Renal Therapeutics 6.10: Therapeutics in Special Populations: Pregnancy & Lactation 6.11: Therapeutics in Special Populations: Paediatrics & Geriatrics 6.12: Primary Health Care, Self-Care, & Harm Minimisation 6.13: Professional Practice, Ethics, & Communication

6.6: Respiratory Therapeutics (Asthma & COPD)

Key Takeaways Explain This Topic AI

In adults and adolescents, SABA-only therapy is no longer recommended as sole treatment; as-needed low-dose budesonide-formoterol is the preferred Step 1 reliever.

In children aged 5 years and under, SABA via a pMDI and spacer remains the preferred reliever; ICS-formoterol is not recommended under 12 years of age.

COPD-X guidelines require a post-bronchodilator FEV1/FVC < 0.7 to confirm diagnosis; ICS monotherapy is contraindicated in COPD due to increased risk of pneumonia.

Spacers should be washed monthly with dishwashing liquid and left to drip dry without rinsing or wiping, as wiping creates an electrostatic charge that traps drug particles.

Acute COPD exacerbation management includes SABA via spacer, oral prednisolone (30-50 mg daily for 5 days), target oxygen of 88-92% to prevent hypercapnia, and antibiotics if indicated.

Last updated: July 2026

Respiratory Therapeutics in Australian Practice

In Australia, the management of asthma is guided by the National Asthma Council's Australian Asthma Handbook, while chronic obstructive pulmonary disease (COPD) is managed using the COPD-X Plan (developed by the Lung Foundation Australia and TSANZ). Pharmacists play a pivotal role in stepwise therapy optimization, inhaler device selection, technique counselling, and acute exacerbation management.

1. Stepwise Asthma Management (Adults & Adolescents)

The Australian Asthma Handbook emphasizes a major paradigm shift: SABA-only therapy (e.g. salbutamol alone) is no longer recommended as the sole treatment for asthma in adults and adolescents. Regular or frequent SABA use without an inhaled corticosteroid (ICS) increases the risk of severe exacerbations and asthma-related death due to untreated airway inflammation.

Stepwise Pharmacotherapy Algorithm (Age ≥ 12 Years)

Step 1 (Mild Asthma) : Preferred option is as-needed low-dose budesonide-formoterol (e.g., Budesonide-formoterol 200/6 mcg, one inhalation as-needed for symptoms). This provides rapid bronchodilation via formoterol (which has an onset of action as fast as salbutamol) combined with the anti-inflammatory controller budesonide, reducing the risk of severe exacerbations by 60% compared to SABA alone.

Step 2 : Preferred options are regular daily low-dose ICS (e.g., fluticasone propionate 100 mcg daily) plus as-needed SABA, OR as-needed low-dose budesonide-formoterol for symptom relief.

Step 3 : Preferred option is maintenance and reliever therapy (MART) using a low-dose ICS-formoterol combination (e.g., budesonide-formoterol 100/6 or 200/6, 1-2 inhalations daily plus as-needed for symptoms), OR regular maintenance low-dose ICS-LABA (e.g., fluticasone furoate-vilanterol) plus as-needed SABA.

Step 4 : Preferred option is medium-dose ICS-formoterol MART , OR regular maintenance medium-dose ICS-LABA plus as-needed SABA.

Step 5 : Maintenance high-dose ICS-LABA plus add-on therapies (such as the LAMA tiotropium, or biologic agents like omalizumab for allergic asthma, mepolizumab for eosinophilic asthma). Refer to a specialist.

Pediatric Stepwise Management (Children ≤ 5 Years)

In children aged 5 years and under, SABA (salbutamol) via a pressurised metered-dose inhaler (pMDI) with a spacer remains the preferred reliever therapy.

Step 1 : As-needed SABA.

Step 2 : Daily preventer therapy with low-dose ICS (e.g., fluticasone propionate 50 mcg BD) or oral montelukast.

Note: ICS-formoterol as-needed is not recommended or approved for children under 12 years of age in Australia.

2. Chronic Obstructive Pulmonary Disease (COPD) Management

COPD is characterized by persistent, progressive respiratory symptoms and airflow limitation that is not fully reversible. Management is guided by the COPD-X guidelines.

Diagnosis

Spirometry is required to confirm COPD diagnosis: a post-bronchodilator FEV1/FVC < 0.70 .

Stepwise Pharmacotherapy

Pharmacotherapy aims to optimize function, prevent symptoms, and reduce exacerbations.

Mild Symptoms / Intermittent Dyspnoea : Short-acting bronchodilator as-needed — either a SABA (salbutamol) or a SAMA (ipratropium).

Persistent Symptoms (Step Up) : Long-acting bronchodilator — either a LAMA (e.g., tiotropium, glycopyrronium) or a LABA (e.g., indacaterol, salmeterol). LAMAs are generally preferred over LABAs for their superior efficacy in reducing exacerbation rates.

Severe Symptoms / Frequent Exacerbations (Step Up) : Dual long-acting bronchodilator therapy ( LAMA + LABA , e.g., glycopyrronium-indacaterol, umeclidinium-vilanterol).

Triple Therapy (LAMA + LABA + ICS) : Reserved for patients who experience recurrent exacerbations (e.g., ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization in the past year) despite dual LAMA + LABA therapy, and who have blood eosinophils ≥ 300 cells/microliter or a history of asthma.

Important Trap: ICS monotherapy is contraindicated in COPD because it increases the risk of pneumonia without providing clinical benefit.

3. Inhaler Device Selection & Technique Counselling

Device selection and correct technique are critical for therapeutic success. Pharmacists must assess and train patients on their devices at every opportunity.

Device Comparison

Device Type Mechanism / Requirements Key Counselling Points

Pressurised Metered-Dose Inhaler (pMDI) Requires coordination between actuation and inhalation. Delivers aerosol. Breathe out gently, place lips firmly around mouthpiece, start to breathe in slowly and deeply, actuate the inhaler, continue to inhale slowly, hold breath for 10 seconds.

pMDI with Spacer Overcomes coordination issues. Reduces oropharyngeal deposition. Spacer cleaning : Wash once a month in warm water with dishwashing liquid. Do not rinse. Do not wipe dry; allow to drip dry (air dry). Wiping or rinsing creates an electrostatic charge that attracts drug particles to the walls, reducing dose delivery.

Dry Powder Inhaler (DPI) (e.g., Turbuhaler, Accuhaler) Breath-activated. Requires a rapid, deep, and forceful inhalation to aerosolize the powder. Unsuitable for patients with acute severe dyspnoea, children under 8 years, or patients with poor inspiratory flow. Instruct patient to breathe out fully away from the device before inhaling.

ICS Counselling

For all ICS-containing inhalers (including MART therapies), patients must rinse their mouth with water and spit it out after use. This prevents local adverse effects, including oral candidiasis (thrush) and dysphonia (hoarseness).

  • 4. Acute Exacerbation Management
  • Acute Asthma Exacerbation (Moderate-to-Severe)

Bronchodilators : Salbutamol via pMDI + spacer: 4-12 puffs, repeating every 20 minutes for the first hour if necessary.

Systemic Corticosteroids : Oral prednisolone (30-50 mg daily for 5-7 days for adults; 1 mg/kg up to 50 mg daily for children for 3-5 days).

Oxygen : Maintain target SpO2 of 93-95% (92-95% in pregnant patients).

Acute COPD Exacerbation

Bronchodilators : Salbutamol (2-6 puffs) via pMDI + spacer every 2-4 hours. Ipratropium may be added.

Systemic Corticosteroids : Oral prednisolone (30-50 mg daily for 5 days). Long courses do not offer extra benefit and increase side effects.

Controlled Oxygen : Target oxygen saturation of 88-92% . High-flow oxygen must be avoided in patients with COPD, as it can cause hypoventilation, hypercapnia, and respiratory acidosis due to loss of their hypoxic drive.

Antibiotics : Indicated only if the patient has signs of clinical infection, defined by at least two cardinal symptoms (increased dyspnoea, increased sputum volume, or increased sputum purulence).

First-line : Amoxicillin 500 mg three times daily for 5 days, OR Doxycycline 200 mg on Day 1, then 100 mg daily for a total of 5 days.